title: Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients.
abstract: OBJECTIVE
  This study was designed to investigate survival after curative resection of colorectal liver metastases in patients with expanded indications.
  
  
  METHODS
  A total of 501 patients had 545 liver resections for metastatic colorectal cancer. There were no predefined criteria for resectability with regard to the number or size of the tumors, locoregional invasion, or extrahepatic disease, except that resection had potential to be complete and macroscopically curative. All patients who had curative hepatic resection were advised to start postoperative adjuvant chemotherapy.
  
  
  RESULTS
  A total of 259 patients had expanded indications (52 percent), including 14 with liver metastases >10 cm, 194 with bilateral deposits, 140 with four or more liver metastases, and 73 with extrahepatic disease. The overall actuarial survival rates at one, three, five, and ten years were 88, 67, 45, and 36 percent, respectively, for patients with classic indications and 84, 53, 34, and 24 percent, respectively, for patients with expanded indications (P = 0.0009). In the group of expanded indications, there were more patients who received preoperative than postoperative chemotherapy: 72 (28 percent) vs. 18 (7 percent; P < 0.0001), and 148 (70 percent) vs. 131 (61 percent; P = 0.0466). In a multivariate analysis, four or more liver metastases and extrahepatic disease were independent predictors of poor outcome. Adjuvant chemotherapy significantly improved survival (P = 0.0002).
  
  
  CONCLUSIONS
  This study suggested that liver resection should be indicated in patients with expanded indications. The extent of the benefits of preoperative and postoperative chemotherapy needs to be quantitated.
authors.affiliation: Department of Surgery, Hospital Universitari de Bellvitge, Barcelona, Spain. cgd.jfigueras@htrueta.scs.es
authors.forename: Juan
authors.initials: J
authors.lastname: Figueras
authors.forename: Jaume
authors.initials: J
authors.lastname: Torras
authors.forename: Carlos
authors.initials: C
authors.lastname: Valls
authors.forename: Laura
authors.initials: L
authors.lastname: Llado
authors.forename: Emilio
authors.initials: E
authors.lastname: Ramos
authors.forename: Joan
authors.initials: J
authors.lastname: Marti-Ragué
authors.forename: Teresa
authors.initials: T
authors.lastname: Serrano
authors.forename: Juan
authors.initials: J
authors.lastname: Fabregat
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D015179:Colorectal Neoplasms / Q000401:mortality / Q000473:pathology*; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000556:secondary* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D012189:Retrospective Studies; D015996:Survival Rate